EUCTR2015-005382-23-FR进行中（未招募）1 期
Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin’s Lymphoma
Immune Design Ltd0 个研究点目标入组 52 人开始时间: 2016年10月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Follicular low grade NHL: either treatment naïve or relapsed or refractory following at least one prior treatment. In Part 1 Dose
- •Escalation only, in addition to follicular NHL, marginal zone B cell lymphomas: either treatment
- •naïve or relapsed or refractory following at
- •least one prior treatment.
- •2. Tumor mass(es) accessible for intratumoral injection and are being considered for local radiation therapy and at least one additional site of disease outside the radiation field for assessment of distal (abscopal) response
- •3. = 18 years of age
- •4. Life expectancy of = 6 months per the investigator
- •5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •6. ECG without evidence of clinically significant arrhythmia or ischemia
- •7. If female of childbearing potential (FCBP), willing to undergo pregnancy testing and agrees to use at least one highly effective or two effective contraceptive methods during the dosing period and for three months after last study treatment, or if receiving pembrolizumab, four
- •months after last treatment.
- •8. If male and sexually active with a FCBP, must agree to use highly effective contraception such as latex condom during the dosing period and for three months after last study treatment, or if receiving
- •pembrolizumab, four months after last treatment
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Cancer therapies, including chemotherapy, radiation (non-study
- •regimen related), biologics or kinase inhibitors, G-CSF or GM-CSF within
- •4 weeks prior to the first scheduled G100 dose
- •2. Investigational therapy within 4 weeks prior to G100 dosing
- •3. Prior administration of other intratumoral immunotherapeutics
- •4. Inadequate organ function including:
- •a. Marrow: Peripheral blood leukocyte count (WBC) < 3000/mm3, absolute neutrophil count = 1500/mm3,
- •platelets < 75000/mm3, or haemoglobin < 10 gm/dL
- •b. Hepatic: alanine aminotransferase (ALT), and aspartate aminotransferase (AST) > 2.5 x ULN, total
- •serum bilirubin > 1.5 x ULN (patients with Gilbert's Disease may be included if their total
- •bilirubin is
- •=3.0 mg/dL)
- •c. Renal: Creatinine > 1.5x ULN
- •d. Other: INR (prothrombin time ratio) or partial thromboplastin time
- •(PTT) >1.5 x ULN
- •5. Significant immunosuppression from:
- •a. Concurrent, recent (= 4 weeks ago) or anticipated treatment with systemic corticosteroids at any
- •b. Other immunosuppressive medications such as methotrexate, cyclosporine, azathioprine or
- •conditions such as common variable hypogammaglobulinemia
- •6. Pregnant or nursing
- •7. Myocardial infarction within 6 months of study initiation, active cardiac ischemia or New York
- •Heart Association (NYHA) Grade III or IV heart failure
- •8. History of other cancer within 2 years (except non-melanoma cutaneous malignancies and cervical
- •carcinoma in situ)
- •9. Recent (< 1 week ago) clinically significant infection, active tuberculosis or evidence of
- •active hepatitis B, hepatitis C or HIV infection
- •10. Central nervous system involvement with lymphoma, including parenchymal and leptomeningeal
- •11. Significant autoimmune disease, including active non-infectious pneumonitis, with the exception
- •of alopecia, vitiligo, hypothyroidism or other conditions that have never been clinically active or
- •were transient and have completely resolved and require no ongoing therapy
- •12. Psychiatric, other medical illness or other condition that in the opinion of the PI prevents
- •compliance with study procedures or ability to provide valid informed consent
- •13. History of significant adverse or allergic reaction to any component of G100 including egg
- •lecithin, and if enrolled in Part 2, anti-PD-1 antibodies
- •14. Use of anti-coagulant agents or history a significant bleeding
- •diathesis. (If a superficial lymph node or subcutaneous mass is to be
- •injected, patients on agents such as non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, or
- •clopidogrel are eligible and these agents do not have to be withheld. For procedures with moderate
- •or significant risk of bleeding, long-acting agents such as aspirin or clopidogrel should be
- •discussed with the Medical Monitor and may need to be discontinued before G100 therapy.
- •For patients enrolled in Part 2 with the potential to receive pembrolizumab:
- •15. History of interstitial lung disease
- •16. Received a live virus vaccine within 30 days of planned study start
- •17. Has undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years.
- •(Subjects who have had a transplant greater than 5 years ago are eligible as long as there are no
- •symptoms of GVHD.)
- •18. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD- L2 agent or if the
- •patient has previously participated in Merck MK-3475
- •clinical trials.
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/2 Study of G100 Therapy injected directly into the tumor or in combination with Pembrolizumab of patients with Follicular non-Hodgkin's Lymphoma.follicular non-Hodgkin's lymphomaMedDRA version: 19.0 Level: LLT Classification code 10067070 Term: Follicular B-cell non-Hodgkin's lymphoma System Organ Class: 100000004864EUCTR2015-005382-23-ESImmune Design Ltd40
进行中（未招募）
1 期
A Phase 1/2 Study of G100 Therapy injected directly into the tumor or in combination with Pembrolizumab or Rituximab in patients with Follicular non-Hodgkin's Lymphoma.EUCTR2015-005382-23-GBImmune Design Ltd143
终止
1 期
Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)Follicular Low Grade Non-Hodgkin's LymphomaNCT02501473Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)52
进行中（未招募）
不适用
A Phase II Clinical Trial to Evaluate Intratumoral Injection of a Depot Formulation of Paclitaxel (DTS-301) as Neoadjuvant Therapy of Patients with Breast CancerInvasive primary breast cancerEUCTR2005-001417-18-ATDIATOS S.A.10
进行中（未招募）
不适用
A phase II Clinical Trial to Evaluate Intratumoral Injection of a Depot Formulation of Paclitaxel (DTS-301) as Neoadjuvant Therapy of Patients with Breast CancerInvasive primary breast cancerEUCTR2005-001417-18-HUDIATOS S.A.10